Cite
HARVARD Citation
Kavanagh, J. et al. (2005). Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. International journal of gynecological cancer. 15 (4), pp. 593-600. [Online].